Clinical Trial Update: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab [Phase 1, Phase 2]

View source ↗

Summary

BeiGene announced completion and posted results for a Phase 1/2 study of BGB-10188 as monotherapy and in combination with zanubrutinib and tislelizumab across m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma
• Solid Tumor

Drugs mentioned

• BGB-10188 (BGB-10188)
• Tislelizumab (tislelizumab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: BeiGene | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-02-20